Literature DB >> 25940082

In Vitro Testing for Orally Inhaled Products: Developments in Science-Based Regulatory Approaches.

Ben Forbes1, Per Bäckman, David Christopher, Myrna Dolovich, Bing V Li, Beth Morgan.   

Abstract

This article is part of a series of reports from the "Orlando Inhalation Conference-Approaches in International Regulation" which was held in March 2014, and coorganized by the University of Florida and the International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS). The goal of the conference was to foster the exchange of ideas and knowledge across the global scientific and regulatory community in order to identify and help move towards strategies for internationally harmonized, science-based regulatory approaches for the development and marketing approval of inhalation medicines, including innovator and second entry products. This article provides an integrated perspective of case studies and discussion related to in vitro testing of orally inhaled products, including in vitro-in vivo correlations and requirements for in vitro data and statistical analysis that support quality or bioequivalence for regulatory applications.

Mesh:

Substances:

Year:  2015        PMID: 25940082      PMCID: PMC4476981          DOI: 10.1208/s12248-015-9763-3

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  78 in total

1.  In vivo pharmacokinetics and pharmacodynamics in drug development using positron-emission tomography.

Authors:  E O. Aboagye; P M. Price; T Jones
Journal:  Drug Discov Today       Date:  2001-03-01       Impact factor: 7.851

2.  Dry powder inhaler device influence on carrier particle performance.

Authors:  Martin J Donovan; Sin Hyen Kim; Venkatramanan Raman; Hugh D Smyth
Journal:  J Pharm Sci       Date:  2011-11-17       Impact factor: 3.534

3.  Dissolution techniques for in vitro testing of dry powders for inhalation.

Authors:  Sabine May; Birte Jensen; Markus Wolkenhauer; Marc Schneider; Claus Michael Lehr
Journal:  Pharm Res       Date:  2012-04-20       Impact factor: 4.200

4.  Drug permeability in 16HBE14o- airway cell layers correlates with absorption from the isolated perfused rat lung.

Authors:  Fergus Manford; Ann Tronde; Ann-Britt Jeppsson; Nilesh Patel; Fredrik Johansson; Ben Forbes
Journal:  Eur J Pharm Sci       Date:  2005-09-08       Impact factor: 4.384

5.  Evaluation of the Respimat Soft Mist Inhaler using a concurrent CFD and in vitro approach.

Authors:  P Worth Longest; Michael Hindle
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2009-06       Impact factor: 2.849

6.  The effect of roflumilast in addition to LABA/LAMA/ICS treatment in COPD patients.

Authors:  Wilfried De Backer; Wim Vos; Cedric Van Holsbeke; Samir Vinchurkar; Rita Claes; Annemie Hufkens; Paul M Parizel; Lieven Bedert; Jan De Backer
Journal:  Eur Respir J       Date:  2014-05-02       Impact factor: 16.671

7.  In vitro monodisperse aerosol deposition in a mouth and throat with six different inhalation devices.

Authors:  W H DeHaan; W H Finlay
Journal:  J Aerosol Med       Date:  2001

8.  Drug absorption from the isolated perfused rat lung--correlations with drug physicochemical properties and epithelial permeability.

Authors:  Ann Tronde; Bo Nordén; Ann-Britt Jeppsson; Per Brunmark; Elisabeth Nilsson; Hans Lennernäs; Ursula Hultkvist Bengtsson
Journal:  J Drug Target       Date:  2003-01       Impact factor: 5.121

9.  The influence of relative humidity on particulate interactions in carrier-based dry powder inhaler formulations.

Authors:  R Price; P M Young; S Edge; J N Staniforth
Journal:  Int J Pharm       Date:  2002-10-10       Impact factor: 5.875

10.  Defining the critical material attributes of lactose monohydrate in carrier based dry powder inhaler formulations using artificial neural networks.

Authors:  Hanne Kinnunen; Gerald Hebbink; Harry Peters; Jagdeep Shur; Robert Price
Journal:  AAPS PharmSciTech       Date:  2014-05-16       Impact factor: 3.246

View more
  9 in total

1.  A new hypothesis to investigate bioequivalence of pharmaceutical inhalation products.

Authors:  Maryam Khoubnasabjafari; Elaheh Rahimpour; Morteza Samini; Vahid Jouyban-Gharamaleki; Lan Chen; Donghao Chen; Hak-Kim Chan; Abolghasem Jouyban
Journal:  Daru       Date:  2019-03-07       Impact factor: 3.117

2.  In Vivo-Relevant Transwell Dish-Based Dissolution Testing for Orally Inhaled Corticosteroid Products.

Authors:  Masahiro Sakagami; Hua Li; Jügen Venitz
Journal:  Pharm Res       Date:  2019-05-09       Impact factor: 4.200

3.  Current Scientific and Regulatory Approaches for Development of Orally Inhaled and Nasal Drug Products: Overview of the IPAC-RS/University of Florida Orlando Inhalation Conference.

Authors:  Guenther Hochhaus; Craig Davis-Cutting; Martin Oliver; Sau L Lee; Svetlana Lyapustina
Journal:  AAPS J       Date:  2015-06-02       Impact factor: 4.009

Review 4.  Bioequivalence Evaluations of Generic Dry Powder Inhaler Drug Products: Similarities and Differences Between Japan, USA, and the European Union.

Authors:  Ryosuke Kuribayashi; Toru Yamaguchi; Hanaka Sako; Tomoko Takishita; Kazunori Takagi
Journal:  Clin Pharmacokinet       Date:  2017-03       Impact factor: 6.447

5.  Pharmacokinetics of the Inhaled Selective Glucocorticoid Receptor Modulator AZD5423 Following Inhalation Using Different Devices.

Authors:  Johanna Melin; Susanne Prothon; Charlotte Kloft; Adriaan Cleton; Carl Amilon; Carin Jorup; Per Bäckman; Bo Olsson; Ulrika Wählby Hamrén
Journal:  AAPS J       Date:  2017-03-09       Impact factor: 4.009

6.  Particle size and gastrointestinal absorption influence tiotropium pharmacokinetics: a pilot bioequivalence study of PUR0200 and Spiriva HandiHaler.

Authors:  Jason Perry; Brian Trautman; Joe Takher-Smith; Steve Kramer; Katie Kane; Michael Silverman; Lisa Tan; Scott Haughie; Wolfram Richter; Valentin Kirkov; Sacha Arsova; Jonathan Ward; David L Hava
Journal:  Br J Clin Pharmacol       Date:  2019-01-15       Impact factor: 4.335

7.  Preclinical Development of Orally Inhaled Drugs (OIDs)-Are Animal Models Predictive or Shall We Move Towards In Vitro Non-Animal Models?

Authors:  Dania Movia; Adriele Prina-Mello
Journal:  Animals (Basel)       Date:  2020-07-24       Impact factor: 2.752

8.  Effect of the Route of Administration and PEGylation of Poly(amidoamine) Dendrimers on Their Systemic and Lung Cellular Biodistribution.

Authors:  Qian Zhong; Olivia M Merkel; Joshua J Reineke; Sandro R P da Rocha
Journal:  Mol Pharm       Date:  2016-05-13       Impact factor: 4.939

9.  Design and development of a biorelevant simulated human lung fluid.

Authors:  Mireille Hassoun; Paul G Royall; Mark Parry; Richard D Harvey; Ben Forbes
Journal:  J Drug Deliv Sci Technol       Date:  2018-10       Impact factor: 3.981

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.